1. Home
  2. SII vs ARQT Comparison

SII vs ARQT Comparison

Compare SII & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SII
  • ARQT
  • Stock Information
  • Founded
  • SII 2008
  • ARQT 2016
  • Country
  • SII Canada
  • ARQT United States
  • Employees
  • SII N/A
  • ARQT N/A
  • Industry
  • SII Finance: Consumer Services
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • SII Finance
  • ARQT Health Care
  • Exchange
  • SII Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • SII 1.1B
  • ARQT 1.7B
  • IPO Year
  • SII N/A
  • ARQT 2020
  • Fundamental
  • Price
  • SII $69.82
  • ARQT $13.78
  • Analyst Decision
  • SII
  • ARQT Strong Buy
  • Analyst Count
  • SII 0
  • ARQT 6
  • Target Price
  • SII N/A
  • ARQT $18.80
  • AVG Volume (30 Days)
  • SII 167.6K
  • ARQT 2.0M
  • Earning Date
  • SII 08-06-2025
  • ARQT 08-13-2025
  • Dividend Yield
  • SII 1.65%
  • ARQT N/A
  • EPS Growth
  • SII 10.23
  • ARQT N/A
  • EPS
  • SII 1.93
  • ARQT N/A
  • Revenue
  • SII $180,474,000.00
  • ARQT $212,819,000.00
  • Revenue This Year
  • SII $0.57
  • ARQT $61.15
  • Revenue Next Year
  • SII $8.89
  • ARQT $37.98
  • P/E Ratio
  • SII $36.17
  • ARQT N/A
  • Revenue Growth
  • SII 17.97
  • ARQT 100.03
  • 52 Week Low
  • SII $38.41
  • ARQT $7.86
  • 52 Week High
  • SII $69.98
  • ARQT $17.75
  • Technical
  • Relative Strength Index (RSI)
  • SII 78.43
  • ARQT 46.51
  • Support Level
  • SII $66.94
  • ARQT $13.51
  • Resistance Level
  • SII $69.54
  • ARQT $14.31
  • Average True Range (ATR)
  • SII 1.56
  • ARQT 0.61
  • MACD
  • SII 0.11
  • ARQT -0.01
  • Stochastic Oscillator
  • SII 99.18
  • ARQT 46.95

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: